Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

Inclusion Criteria

• •All subjects: (suggest this will reduce duplication)
• •Male or female aged 18-65 yr,
• •Subjects must weigh at least 50 kg to participate in the study. Body mass index (BMI) must be within the range of 18-37 kg/m2 (inclusive
• •Only postmenopausal females or female subjects who report surgical sterilization (women without child bearing potential) will be allowed in this study.
• •Subjects with stable conventional sleep-wake cycle
• •Normal Healthy Volunteers
• •Healthy male or female subjects,
• •must be in good health (as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at Screening).
• •Type II Diabetic Patients
• •Type 2 diabetes diagnosed by American Diabetes Association criteria for at least 3 months prior to screening.
• •Patients either drug naïve or on stable dose of metformin (stable dose for at least 4 weeks prior to Screening). The metformin dose should remain constant during the course of the study.
• •HbA1c 6.5 to 9.5 % inclusive at screening